

DAFTAR PUSTAKA

1. Li H, Liu S, Yu X, Tang S, Tang C. Coronavirus disease 2019 (COVID-19): current status and future perspectives. *Int J Antimicrob Agents*. 2020;55(5):105951.
2. Sahin AR, Erdogan A, Agaoglu pelin M, Dinerti Y. 2019 Novel coronavirus (COVID-19) outbreak: a review of the current literature. *Eurasian J Med Oncol*. 2020;4(1):1–7.
3. Murdaca G, Pioggia G, Negrini S. Vitamin D and Covid-19: an update on evidence and potential therapeutic implications. *Clin Mol Allergy*. 2020;18(1):1–15.
4. Kementerian Kesehatan RI. Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19). 5 ed. Vol. 9. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020. 1–214 hal.
5. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. World Health Organization. 2022 [dikutip 1 September 2022]. Tersedia pada: <https://covid19.who.int/>
6. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. *Eur J Clin Nutr*. 2020;74(11):1498–513.
7. Neurosensum. Indonesian consumer trends 2021 [Internet]. Neurosensum. 2021 [dikutip 25 Mei 2023]. Tersedia pada: <https://neurosensum.com/indonesian-consumer-trends-2021/>
8. Mulyani M, Zaini M, Isnani N, Rahmah M. Profil Penggunaan Vitamin Dan Suplemen Pada Pasien Covid-19 Rawat Inap Di Rumah Sakit Bhayangkara Tk. III Banjarmasin Pada Tahun 2020. *J Insa Farm Indones*. 2022;5(1):87–97.
9. Sabico S, A. Enami M, Sheshah Ema, Aljohani NJ. Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate covid-19: A randomized clinical trial Shaun. *Nutrients*. 2021;13:2170.
10. Gasmi A, Tippairote T, Mujawdiya PK, Peana M, Menzel A, Dadar M, et al. Micronutrients as immunomodulatory tools for COVID-19 management. *Clin Immunol*. 2020;220(July):108545.
11. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths. *Nutrients*. 2020;12(4):1–19.
12. L Bishop E, Ismailova A, Dimeloe S, Hewison M, White JH. Vitamin D

and Immune Regulation: Antibacterial, Antiviral, Anti-Inflammatory. *JBMR Plus*. 2021;5(1):1–23.

13. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, et al. Vitamin D and COVID-19. *Eur J Endocrinol*. 2020;183(5):R133–47.
14. Tanaya GD, Tanaya WM, Syarif AH. Vitamin D Supplementation and COVID-19. *J Respirasi*. 2022;8(1):60–8.
15. Nair R, Maseeh A. Vitamin D: The sunshine vitamin. *J Pharmacol Pharmacother*. 2012;3(2):118–26.
16. Alcala-diaz JF, Limia-perez L, Gomez-huelgas R, Martin-escalante MD, Cortes-rodriguez B, Zambrana-garcia JL, et al. Calcifediol treatment and hospital mortality due to covid-19: A cohort study. *Nutrients*. 2021;13(6):1–13.
17. Niet S De, Trémège M, Coffiner M, Calmes A-FRD, Frix A-N, Gester F, et al. Positive effects of vitamin D supplementation in patients. *Nutrients*. 2022;14(2):1–12.
18. Cerededa E, Bogliolo L, Lobascio F, Barichella M.D M, Lena Zecchinelli M.D A, Pezzoli M.D G, et al. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. *Nutrition*. 2020;82(1):111055.
19. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020;24:91–8.
20. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395(22):565–74.
21. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270–3.
22. Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease covid-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. *Pathogens*. 2020;9(5):1–11.
23. Huang Y, Yang C, Xu X feng, Xu W, Liu S wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin*. 2020;41(9):1141–9.
24. Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. *J Med Virol*. 2020;92(6):639–44.
25. Doremalen N Van, Bushmaker T, J. Munster V. Aerosol and surface

- stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med.* 2020;382(12):1177–9.
26. Arianto D, Rumende M, W Pitoyo C, Djoko Santoso W, Yulianti M. Coronavirus disease 2019. *J Penyakit Dalam Indones.* 2020;7(1):45–67.
 27. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020;10(2):102–8.
 28. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 2020;46(4):586–90.
 29. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016;14(8):523–34.
 30. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. *PLOS Pathog.* 2020;16(8):e1008762.
 31. Gennaro F Di, Pizzol D, Marotta C, Antunes M, Racalbutto V, Veronese N, et al. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. *Int J Environ Res Public Health.* 2020;17(2690):1–11.
 32. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol.* 2020;92(4):424–32.
 33. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China. *SSRN Electron J.* 2020;1–24.
 34. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) [Internet]. World Health Organization. Geneva; 2020. Tersedia pada: <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>
 35. Fan YY, Huang ZT, Li L, Wu MH, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. *Arch Virol.* 2009;154(7):1093–9.
 36. Suresh Kumar VC, Mukherjee S, Harne PS, Subedi A, Ganapathy MK, Patthipati VS, et al. Novelty in the gut: A systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. *BMJ Open Gastroenterol.* 2020;7(1).
 37. Handayani D, Rendra Dwi H, Isbaniah F, Erlina B, Agustin H. Corona

- Virus Disease 2019. *CPD Infect.* 2020;40(2):1–14.
38. Viveiros Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. *Rev Panam Salud Publica/Pan Am J Public Heal.* 2020;44:e40.
 39. Dawei W, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–9.
 40. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269–71.
 41. CDC. COVID-19 treatments and medications [Internet]. Centers for Disease Control and Prevention. 2021 [dikutip 25 Mei 2023]. Tersedia pada: <https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html>
 42. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19. 4 th ed. Burhan E, Susanto AD, Isbaniah F, Nasution SA, Ginanjar E, Pitoyo CW, et al., editor. Jakarta: Perhimpunan dokter paru Indonesia; 2022. 5–149 hal.
 43. Herrmann M, Farrell CJL, Pusceddu I, Fabregat-Cabello N, Cavalier E. Assessment of Vitamin D status - A changing landscape. *Clin Chem Lab Med.* 2017;55(1):3–26.
 44. Rabelo HT, Barroso WBG, Magalhães JL. Micronutrients as an innovation opportunity for the pharmaceutical industry: A case study of vitamin D in Brazil. *Food Sci Nutr Stud.* 2017;1(1):50–60.
 45. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. *Sci Rep.* 2020;10(1):1–9.
 46. Xu Y, Baylink DJ, Chen CS, Reeves ME, Xiao J, Lacy C, et al. The importance of Vitamin D metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. *J Transl Med.* 2020;18(1):1–12.
 47. Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and Novel Actions. *Ann Nutr Metab.* 2018;72(2):87–95.
 48. Augustine little flower, Nair KM, Kulkarni B. Sun exposure as a strategy for acquiring vitamin D in developing countries of tropical region: Challenges & way forward. *Indian J Med Res.* 2021;(154):423–32.
 49. Judistiani RTD, Nirmala SA, Rahmawati M, Ghrahani R, Natalia YA, Sugianli AK, et al. Optimizing ultraviolet B radiation exposure to prevent vitamin D deficiency among pregnant women in the tropical zone: Report

from cohort study on vitamin D status and its impact during pregnancy in Indonesia. *BMC Pregnancy Childbirth*. 2019;19(1):1–9.

50. Vandana Mehta R, Shenoj SD, Balachandran C, Pai S. Minimal erythema response (MED) to solar simulated irradiation in normal Indian skin. *Indian J Dermatol Venereol Leprol*. 2004;70(5):277–9.
51. Bleizgys A. Vitamin D and COVID-19: It is time to act. *Int J Clin Pract*. 2021;75(3):e13748.
52. Bae JH, Choe HJ, Holick MF, Lim S. Association of vitamin D status with COVID-19 and its severity: Vitamin D and COVID-19: a narrative review. *Rev Endocr Metab Disord*. 2022;23(3):579–99.
53. Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-CoV-2 interaction with renin-angiotensin system. *J Am Coll Cardiol*. 2020;75(24):3085–95.
54. Li YC, Kong J, Wei M, Chen Z, Liu SQ, Cao L. 1, 25-Dihydroxyvitamin D₃ is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest*. 2002;110(2):229–38.
55. Shi Y, Liu T, Yao L, Xing Y, Zhao X, Fu J, et al. Chronic Vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. *Sci Rep*. 2017;7(1):1–10.
56. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. *Mol Med Rep*. 2017;16(5):7432–8.
57. Rathod BD, Ahirwar AK, Banerjee S, Joshi PP. Association of vitamin D with the severity of disease and mortality in COVID-19: prospective study in central India. *Ann Afric Med*. 2023;22(1):117–23.
58. Daneshkhan A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. *Aging Clin Exp Res*. 2020;32(10):2141–58.
59. Prasetyo S, Sidharta VM, Wahyuningsih KA, Astiarani Y, Huh I sil. The correlation between vitamin D intake and quality of life in the 17-35 age group. *MKMI*. 2022;18(3):90–7.
60. Holick MF, Binkley NC, Bischoff-ferrari HA, Gordon CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin endocrinology Metab*. 2011;96(7):1911–30.
61. Radujkovic A, Hippchen T, Tiwari-Hecler S, Dreher S. Vitamin D deficiency and outcome of COVID-19 patients. *Clin Med J R Coll Physicians London*. 2020;20(6):E282–3.

62. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J Endocrinol Invest.* 2021;44(4):765–71.
63. Campi I, Gennari L, Merlotti D, Mingiano C, Frosali A, Giovanelli L, et al. Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. *BMC Infect Dis.* 2021;21(1):1–13.
64. Tim skripsi FK UNAND. Pedoman penulisan literatur review. Padang: Fakultas Kedokteran Universitas Andalas; 2020.
65. Elamir YM, Amir H, Lim S, Rana YP, Lopez CG, Feliciano NV, et al. A randomized pilot study using calcitriol in hospitalized COVID-19 patients. *Bone.* 2022;154(1):116175.
66. Cannata-Andía JB, Díaz-Sottolano A, Fernández P, Palomo-Antequera C, Herrero-Puente P, Mouzo R, et al. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D a randomised multicentre international clinical trial. *BMC Med.* 2022;20(1):1–13.
67. Torres M, Casado G, Vigón L, Rodríguez-Mora S, Mateos E, Ramos-Martín F, et al. Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. *Biomed Pharmacother.* 2022;150:112965.
68. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. *JAMA.* Maret 2021;325(11):1053–60.
69. Bychinin M V., Klypa T V., Mandel IA, Yusubaliev GM, Baklaushev VP, Kolyshkina NA, et al. Effect of vitamin D3 supplementation on cellular immunity and inflammatory markers in COVID-19 patients admitted to the ICU. *Sci Rep.* 2022;12(1):1–9.
70. Sarhan N, Abou Warda AE, Sarhan RM, Boshra MS, Mostafa-Hedeab G, ALruwaili BF, et al. Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial. *Med.* 2022;58(10).
71. Domazet Bugarin J, Dosenovic S, Ilic D, Delic N, Saric I, Ugrina I, et al. Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial. *Nutrients.* 2023;15(5).
72. Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. Effects of a 2-week 5000 iu versus 1000 iu vitamin d3 supplementation on recovery of symptoms in patients with mild to moderate covid-19: A randomized clinical trial. *Nutrients.* 2021;13(7):2170.

73. Fernandes AL, Murai IH, Reis BZ, Sales LP, Santos MD, Pinto AJ, et al. Effect of a single high dose of vitamin D3 on cytokines, chemokines, and growth factor in patients with moderate to severe COVID-19. *Am J Clin Nutr.* 2022;115(3):790–8.
74. Bilan N, Dastranji A, Ghalehgolab Behbahani A. Comparison of the SpO₂/FIO₂ ratio and the PaO₂/FIO₂ Ratio in patients with acute lung injury or acute respiratory distress syndrome. *J Cardiovasc Thorac Res.* 2015;7(1):28–31.
75. Ramos-Martínez E, López-Vancell MR, Fernández de Córdova-Aguirre JC, Rojas-Serrano J, Chavarría A, Velasco-Medina A, et al. Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFN γ levels and cathelicidin expression. *Cytokine.* 2018;108:239–46.
76. Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong M-F, et al. High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional multi-centre observational study. *Nutrients.* Desember 2020;12(12):e65785.
77. Charoenngam N, Shirvani A, Reddy N, Vodopivec DM, Apovian CM, Holick MF. Association of vitamin D status with hospital morbidity and mortality in adult hospitalized patients with COVID-19. *Endocr Pract.* 2021;27(4):271–8.
78. Mutair A Al, Mutairi A Al, Zaidi ARZ, Salih S, Alhumaid S, Rabaan AA, et al. Clinical predictors of COVID-19 mortality among patients in intensive care units: A retrospective study. *Int J Gen Med.* 2021;14:3719–28.
79. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. *J Steroid Biochem Mol Biol.* 2020;203:105751.
80. Szymczak I, Pawliczak R. The Active Metabolite of Vitamin D3 as a Potential Immunomodulator. *Scand J Immunol.* Februari 2016;83(2):83–91.
81. Giménez VMM, Sanz RL, Marón FJM, Ferder L, Manucha W. Vitamin D-RAAS connection: An integrative standpoint into cardiovascular and neuroinflammatory disorders. *Curr Protein Pept Sci.* 2020;21(10):948–54.
82. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. *Br J Pharmacol.* Juni 2013;169(3):477–92.
83. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB,

et al. Renin-Angiotensin-Aldosterone System inhibitors and risk of COVID-19. *N Engl J Med*. Juni 2020;382(25):2441–8.

84. Kuznia S, Zhu A, Akutsu T, Buring JE, Camargo Jr CA, Cook NR, et al. Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials. *Ageing Res Rev*. 2023;87:101923.
85. Middelkoop K, Stewart J, Walker N, Delport C, Jolliffe DA, Coussens AK, et al. Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicentre phase 3 double-blind randomised placebo-controlled trial (ViDiKids). *Int J Infect Dis*. 2023;134:63–70.
86. Beran A, Mhanna M, Srouf O, Ayesb H, Stewart JM, Hjouj M, et al. Clinical significance of micronutrient supplements in patients with coronavirus disease 2019: A comprehensive systematic review and meta-analysis. *Clin Nutr ESPEN*. 2022;48:167–77.
87. Ohaegbulam KC, Swalih M, Patel P, Smith MA, Perrin R. Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series. *Am J Ther*. 2020;27(5):e485–90.
88. Lan S-H, Lai C-C, Chang S-P, Lu L-C, Hung S-H, Lin W-T. Vitamin D supplementation and the outcomes of critically ill adult patients: a systematic review and meta-analysis of randomized controlled trials. *Sci Rep*. Agustus 2020;10(1):14261.
89. Tentolouris N, Samakidou G, Eleftheriadou I, Tentolouris A, Jude EB. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression. *Diabetes Metab Res Rev*. 1 Mei 2022;38(4):e3517.
90. Chen J, Mei K, Xie L, Yuan P, Ma J, Yu P, et al. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. *Nutr J*. Oktober 2021;20(1):89.
91. Angelidi AM, Belanger MJ, Lorinsky MK, Karamanis D, Chamorro-Pareja N, Ognibene J, et al. Vitamin D status is associated with in-hospital mortality and mechanical ventilation: a cohort of COVID-19 hospitalized patients. *Mayo Clin Proc*. 2021;96(4):875–86.
92. Yeh C-L, Wu J-M, Chen K-Y, Wu M-H, Yang P-J, Lee P-C, et al. Effects of different routes and forms of vitamin D administration on CD4+ T cell homeostasis and renin-angiotensin system-associated lung injury in obese mice complicated with polymicrobial sepsis. *Biomed Pharmacother*. 2022;156:113961.